PURPOSE: Obesity-related leptin and leptin receptor (OBR) have a relation to the development of cancer and metastasis and also the low survival rate for breast cancer patients. Leptin has been associated with increased aromatase activity and it displays functional cross-talk with estrogen. This study was designed to determine the relationship between the expression of leptin and OBR in breast cancer tissue and the prognosis of early-stage breast cancer patients, and especially for the tamoxifen-treated patients. MATERIALS AND METHODS: Ninety-five patients with early-stage breast cancer and who had undergone surgical treatment at Kyung Hee University Hospital between January 1994 and June 2004 were analyzed. The surgical specimens underwent immunohistochemical analysis for leptin and OBR. The patients' survival and clinical characteristics were obtained from the medical records. RESULTS: Of the 95 patients, 79 (83%) and 32 (33.7%) showed the expression of leptin and OBR in breast cancer tissue, respectively. The expression of leptin and OBR in breast cancer tissue was not significantly related to the clinicopathological characteristics, including obesity, the expression of hormonal receptor, the HER-2/neu expression, menopause, stage and the nuclear grade. The expression of leptin and OBR was not significantly related to the overall disease-free survival (DFS). For the tamoxifen-treated postmenopausal obese patients, the DFS of the leptin-positive group was higher than that of the leptin-negative group (p=0.017). CONCLUSION: The expression of leptin and OBR in breast cancer tissue may be not a prognostic factor for disease-free survival of breast cancer patients. In the future, further studies are needed to determine whether leptin expression could be a predictive factor for tamoxifen therapy in the postmenopausal obese subgroup among the early breast cancer patients.
PURPOSE:Obesity-related leptin and leptin receptor (OBR) have a relation to the development of cancer and metastasis and also the low survival rate for breast cancerpatients. Leptin has been associated with increased aromatase activity and it displays functional cross-talk with estrogen. This study was designed to determine the relationship between the expression of leptin and OBR in breast cancer tissue and the prognosis of early-stage breast cancerpatients, and especially for the tamoxifen-treated patients. MATERIALS AND METHODS: Ninety-five patients with early-stage breast cancer and who had undergone surgical treatment at Kyung Hee University Hospital between January 1994 and June 2004 were analyzed. The surgical specimens underwent immunohistochemical analysis for leptin and OBR. The patients' survival and clinical characteristics were obtained from the medical records. RESULTS: Of the 95 patients, 79 (83%) and 32 (33.7%) showed the expression of leptin and OBR in breast cancer tissue, respectively. The expression of leptin and OBR in breast cancer tissue was not significantly related to the clinicopathological characteristics, including obesity, the expression of hormonal receptor, the HER-2/neu expression, menopause, stage and the nuclear grade. The expression of leptin and OBR was not significantly related to the overall disease-free survival (DFS). For the tamoxifen-treated postmenopausal obesepatients, the DFS of the leptin-positive group was higher than that of the leptin-negative group (p=0.017). CONCLUSION: The expression of leptin and OBR in breast cancer tissue may be not a prognostic factor for disease-free survival of breast cancerpatients. In the future, further studies are needed to determine whether leptin expression could be a predictive factor for tamoxifen therapy in the postmenopausal obese subgroup among the early breast cancerpatients.
Entities:
Keywords:
Early breast cancer; Leptin; OBR; Obesity; Postmenopause; Tamoxifen
Authors: J F Savouret; M Rauch; G Redeuilh; S Sar; A Chauchereau; K Woodruff; M G Parker; E Milgrom Journal: J Biol Chem Date: 1994-11-18 Impact factor: 5.157
Authors: Adana A M Llanos; John B Aremu; Ting-Yuan David Cheng; Wenjin Chen; Marina A Chekmareva; Elizabeth M Cespedes Feliciano; Bo Qin; Yong Lin; Coral Omene; Thaer Khoury; Chi-Chen Hong; Song Yao; Christine B Ambrosone; Elisa V Bandera; Kitaw Demissie Journal: Front Endocrinol (Lausanne) Date: 2022-06-29 Impact factor: 6.055
Authors: Adana A M Llanos; Yong Lin; Wenjin Chen; Song Yao; Jorden Norin; Marina A Chekmareva; Coral Omene; Lei Cong; Angela R Omilian; Thaer Khoury; Chi-Chen Hong; Shridar Ganesan; David J Foran; Michael Higgins; Christine B Ambrosone; Elisa V Bandera; Kitaw Demissie Journal: Breast Cancer Res Date: 2020-02-11 Impact factor: 6.466